Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-04-04

FDA Approved: AMBRISENTAN — Supplemental Application (Zydus Lifesciences Limited)

View source ↗

Summary

FDA approves a supplemental application from Zydus Lifesciences Limited for ambrisentan, granting regulatory approval of a generic version. The drug is used to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)